> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Latruvo BLA Approval Revoked
- URL: https://www.fdaweb.com/lilly-latruvo-bla-approval-revoked/
- Published: 2020-07-17T12:00:00.000Z
- Updated: 2026-09-14T16:21:36.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147221

*Federal Register* notice: FDA has announced it is revoking approval of an Eli Lilly BLA for Lartruvo (olaratumab), indicated for combination use with doxorubicin for treating adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. The company requested the accelerated-approval drug be withdrawn after a required confirmatory study did not meet the primary endpoints of overall survival. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-07-17/pdf/2020-15516.pdf?ref=fdaweb.com).